Corbus Pharmaceuticals Holdings, Inc. cash flow to debt ratio of -3.95K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Corbus Pharmaceuticals Holdings, Inc.'s free cash flow has decreased 54.32% from $-41.79M last year to $-64.50M, signaling decreasing performance

Corbus Pharmaceuticals Holdings, Inc.'s debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability.

Corbus Pharmaceuticals Holdings, Inc.'s debt has increased relative to shareholder equity from 0.02 last year to 0.04 today, signaling weakened financials

Corbus Pharmaceuticals Holdings, Inc. has a net cash position, so leverage is healthy.

Corbus Pharmaceuticals Holdings, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Corbus Pharmaceuticals Holdings, Inc. has insufficient data to evaluate this check.

Corbus Pharmaceuticals Holdings, Inc.'s short-term assets of $166.95M exceed its short-term liabilities of $20.69M

Corbus Pharmaceuticals Holdings, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -87.05%, is lower than 15.00%, indicating bad performance

Corbus Pharmaceuticals Holdings, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Corbus Pharmaceuticals Holdings, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Corbus Pharmaceuticals Holdings, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Corbus Pharmaceuticals Holdings, Inc. has negative free cash flow, indicating cash burn

Corbus Pharmaceuticals Holdings, Inc.'s yearly earnings has decreased 95.32% since last year from $-40.21M to $-78.54M, signaling decreasing performance

Corbus Pharmaceuticals Holdings, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -100.35% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Corbus Pharmaceuticals Holdings, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Corbus Pharmaceuticals Holdings, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Corbus Pharmaceuticals Holdings, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Corbus Pharmaceuticals Holdings, Inc. has insufficient data to evaluate this check.

Corbus Pharmaceuticals Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Corbus Pharmaceuticals Holdings, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Corbus Pharmaceuticals Holdings, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Corbus Pharmaceuticals Holdings, Inc. has insufficient data to evaluate this check.

Corbus Pharmaceuticals Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Corbus Pharmaceuticals Holdings, Inc. has a price-to-book ratio of 1.80x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Corbus Pharmaceuticals Holdings, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue